] . (1998). Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. J Infec Dis, 177, 310-319. presented at the 02/1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466516
. (1998). Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infec Dis, 177, 1230-46. presented at the 1998.
. (1999). A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infec Dis, 180, 290-8. presented at the 1999.
. (1999). Immunization with envelope MN rap 120 vaccine in human immunodeficiency virus infected pregnant women. J Infec Dis, 180, 1080-8. presented at the 1999.
. (2003). Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine, 21-22, 2933-2947. presented at the 2003.
. (2007). Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers. In AIDS Vaccine 2007 Conference. presented at the 20/08/2007, Seattle, WA. Retrieved from http://www.vaccineenterprise.org/conference_archive/2007/index.html